ACM-Pivotal Offers Eco-Friendly Branding Solutions for Pharma Commercialization Efforts
Customized Specimen Collection Kits Provide Convenience, Accuracy and Promotion Ideal for Post-Marketing Studies
Rochester, NY, Sept. 22, 2008 – ACM-Pivotal <
ACM-Pivotal will be showcasing its KitKaddy and collection kits, along with its safety testing expertise, at the 11th Registries and Post Approval Studies Congress <
ACM-Pivotal has been shipping KitKaddy and lab collection kits to investigator sites globally since 2003 and has received positive response from both investigators and sponsors. Customer demand and increased post-marketing studies have prompted ACM-Pivotal to offer a white-labeled solution to help increase brand awareness of new drugs available on the market.
“Our KitKaddy and lab collection kits are now multipurpose. Not only are they ideal for large safety studies, they provide an additional avenue for sponsors to reinforce their brands to a key audience,” said Elena Logan, VP, Clinical Trials. “With the continued emphasis on post-marketing safety studies, we are pleased to have a solution that is very well aligned with these commitments.”
The KitKaddy is organized with 24 custom visit and protocol-specific laboratory supply trays with the capacity to support large safety studies. Designed specifically for each clinical trial, all the necessary draw supplies are included. ACM-Pivotal’s collection kits enable clinicians to easily adhere to the specimen collection portion of protocols. Furthermore, the kits are assembled in a facility using 100 percent wind energy and manufactured using paperboard that is 100 percent recyclable and made from a renewable resource. The high-quality kits are produced in an ISO 9002 certified facility.
For more information and photos, please visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025